¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"tRNA synthetase recognition site"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® recognition, perception ÇÑ±Û ÀÎÁö, ÀνÄ, ÀçÀνÄ
¼³¸í   
  »ýü°¡ Àڱ⠶Ǵ Àڱ⿡°Ô ÀûÇÕÇÑ °ÍÀ¸·Î ºñÀڱ⸦ ½Äº°Çϴ °Í. »ýü°¡ ¾î¶°ÇÑ ÀÚ±ØÀ» ¼ö¿ëü µîÀ¸·Î ¼ö¿ëÇÏ¿© ½Äº°ÇÑ °á°ú ÀϾ º¯È­, ¹ÝÀÀ ¶Ç´Â Çൿ±îÁö¸¦ Æ÷ÇÔÇØ¼­ ¸»Çϴ °æ¿ìµµ ÀÖ´Ù. Ç׿øÀÚ±ØÀ» ¹ÞÀº ¸é¿ª´ã´ç¼¼Æ÷¿¡ ÀϾ´Â º¯È­¿Í °°Àº ¹°Áú¼öÁØÀÇ Çö»óÀ¸·ÎºÎÅÍ °íµîµ¿¹°¿¡¼­ °³Ã¼ÀÇ ÀÎÁö µîÀÌ ÀÖ´Ù. ¶ÇÇÑ º¸´Ù °íÂ÷ÀÇ Ãß»óÀûÀΠ°³³äÀ¸·Î¼­ °¨°¢¿¡ À־ÀÇ ÀÎÁö³ª ÁßÃ߽ŰæÀÇ ´É·Â¿¡ °ü¿©Çϴ ÆÐÅÏÀνĠµîÀÌ ÀÖ´Ù. 
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antigen-recognition site
    Ç׿øÀÎÁöºÎÀ§
  • glutathione synthetase
    ±Û·çŸƼ¿ÂÇÕ¼ºÈ¿¼Ò
  • synthetase
    ÇÕ¼ºÈ¿¼Ò
  • antigen recognition
    Ç׿øÀνÄ
  • immunological recognition
    ¸é¿ªÀνÄ
  • pattern recognition
    ÆÐÅÏÀνÄ, ¸ð¾çÀνÄ
  • recognition
    1. ÀνÄ, ÀÎÁö 2. ½ÂÀÎ
  • speech recognition threshold
    ¾ð¾î°¨Áö¹®Åΰª
  • self recognition
    ÀÚ±âÀνÄ
  • antibody-binding site
    Ç×ü°áÇÕºÎÀ§
  • antigen-binding site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-combining site
    Ç׿ø°áÇÕºÎÀ§
  • active site
    Ȱ¼ººÎÀ§
  • binding site
    °áÇÕºÎÀ§
  • combining site
    °áÇÕºÎÀ§
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • recognition
    ÀÎÁö, ÀνÄ
  • synthetase
    ÇÕ¼ºÈ¿¼Ò
  • site
    ºÎÀ§
  • active site
    Ȱ¼ººÎÀ§
  • antigen-binding site
    Ç׿ø°áÇÕºÎÀ§
  • receptor site
    ¼ö¿ëüºÎÀ§
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antigen-recognition site
    Ç׿øÀÎÁöºÎÀ§
  • synthetase
    ÇÕ¼ºÈ¿¼Ò
  • antigen recognition
    Ç׿øÀÎÁö
  • dual recognition hypothesis
    Ç׿øÀÌÁßÀÎÁö°¡¼³
  • immunological recognition
    ¸é¿ªÀÎÁö
  • pattern recognition
    ÆÐÅÏÀνÄ, ¸ð¾çÀνÄ
  • recognition
    ÀÎÁö, ÀνÄ, ÀçÀνÄ
  • self recognition
    ÀÚ±âÀÎÁö
  • speech recognition threshold
    ¾ð¾îÀÎÁö¹®ÅÎ
  • absorption site
    Èí¼öºÎÀ§
  • acceptor site
    ¼ö¿ëºÎÀ§
  • active site
    Ȱ¼ººÎÀ§
  • antibody-binding site
    Ç×ü°áÇÕºÎÀ§
  • antigen-binding site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-combining site
    Ç׿ø°áÇÕºÎÀ§
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antibody to histidyl tRNa synthetase
    È÷½ºÆ¼µô tRNa ÇÕ¼ºÈ¿¼Ò¿¡ ´ëÇÑ Ç×ü
  • antigen recognition site
    Ç׿ø½Äº°ºÎ.
  • gamma-glutamyl cysteine synthetase
    °¨¸¶-±Û·çŸ¹Ð½Ã½ºÅ×ÀÎÇÕ¼ºÈ¿¼Ò
  • heme synthetase
    ÈûÇÕ¼ºÈ¿¼Ò.
  • heme synthetase
    ÇðÇÕ¼ºÈ¿¼Ò.
  • phosphoribosyl pyrophosphate synthetase
    Æ÷½ºÆ÷¸®º¸½ÇÇÇ·ÎÆ÷½ºÆäÀÌÆ®½ÅÅןÁ¦<ÇÕ¼ºÈ¿¼Ò>
  • antigen recognition
    Ç׿øÀÎÁö
  • immunological recognition
    ¸é¿ªÇÐÀûÀÎÁö
  • recognition
    ÀνÄ(ìããÛ).
  • recognition
    ÀÎÁö
  • recognition, self
    ÀÚ±âÀÎÁö
  • absorption site
    Èí¼öÁ¡
  • acceptor site
    ¼ö¿ëºÎÀ§
  • active site
    Ȱ¼ºÀÚ¸®.
  • antibody binding site
    Ç×ü°áÇÕºÎÀ§
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antibody to histidyl tRNa synthetase
    È÷½ºÆ¼µô tRNa ÇÕ¼ºÈ¿¼Ò¿¡ ´ëÇÑ Ç×ü
  • antigen recognition site
    Ç׿ø½Äº°ºÎ.
  • peptidyl-tRNA
    ÆéƼµå-tRNA
  • antigen recognition
    Ç׿øÀÎÁö
  • cystathionine synthetase
    ½Ã½ºÅ¸Æ¼¿À´ÑÇÕ¼ºÈ¿¼Ò(¡­ùêà÷ý£áÈ).
  • delta-aminolevulinic acid synthetase
    µ¨Å¸-¾Æ¹Ì³ë·¹ºÒ¸°»êÇÕ¼ºÈ¿¼Ò
  • dual recognition hypothesis
    Ç׿øÀÌÁßÀÎÁö°¡¼³
  • gamma-glutamyl cysteine synthetase
    °¨¸¶-±Û·çŸ¹Ð½Ã½ºÅ×ÀÎÇÕ¼ºÈ¿¼Ò
  • glutathione synthetase
    ±Û·çŸƼ¿ÂÇÕ¼ºÈ¿¼Ò
  • heme synthetase
    ÇðÇÕ¼ºÈ¿¼Ò.
  • heme synthetase
    ÈûÇÕ¼ºÈ¿¼Ò.
  • histydyl-t-rna synthetase
    Histydyl-t-RNA ÇÕ¼ºÈ¿¼Ò
  • immunological recognition
    ¸é¿ªÇÐÀûÀÎÁö
  • pattern recognition
    ÆÐÅÏÀνÄ
  • pattern recognition
    ÆÐÅÏÀνÄ, ¸ð¾çÀνÄ.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Variations of site
    À§Ä¡º¯ÀÌ
    [¿¾ ¿ë¾î] À§Ä¡ÀÌ»ó
  • Corporal site
    ÀڱøöÅëÀÓ½Å
    [¿¾ ¿ë¾î] ÀÚ±ÃüºÎ
  • Absorption site
    Èí¼öÁ¡
    [¿¾ ¿ë¾î] Èí¼öÃÊÁ¡
  • Fundic site
    ÀڱùٴÚÀÓ½Å
    [¿¾ ¿ë¾î] ÀÚ±ÃÀúºÎ
  • Definitive site
    Âø»óÀÚ¸®
    [¿¾ ¿ë¾î] À§Ä¡¼±Á¤
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • tRNA synthetase recognition site
    tRNA½ÅÅ×Å×À̽º ÀÎÁö(ìãò±)ÀÚ¸®
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • aminoacyl-tRNA synthetase
    ¾Æ¹Ì³ë¾Æ½ÇtRNA ½ÅÅ×Å×À̽º
  • tRNA synthetase
    tRNA½ÅÅ×Å×À̽º
  • recognition site
    ÀνÄ(ìããÛ)ÀÚ¸®
  • aminoacyl-tRNA site
    ¾Æ¹Ì³ë¾Æ½ÇtRNA ÀÚ¸®
  • peptidyl-tRNA site
    ÆéŸÀ̵å-tRNA ÀÚ¸®
  • A-site-P-site moel
    AÀÚ¸® PÀÚ¸® ¸ðµ¨
  • associative recognition
    ¿¬ÇÕ¼ºÀÎ½Ä (æáùêàõìããÛ)
  • dual recognition
    ÀÌÁß ÀνÄ(ì£ñììããÛ)
  • MHC associative recognition
    MHC ¿¬ÇÕÀÎÁö(Ö¤ùêìãò±)
  • multiple codon recognition
    ´Ù(Òý)ÄÚµ· ÀÎÁö(ìãò±)
  • signal recognition protein
    ½ÅÈ£ÀÎÁö´Ü¹éÁú(ãáûÜìãò±Ó±ÛÜòõ)
  • amylose synthetase(synthase)
    "¾Æ¹Ð·Î½º½ÅÅ×Å×À̽º, ¾Æ¹Ð·Î½º½ÅÅ×À̽º"
  • fatty acid synthetase system
    Áö¹æ»ê ÇÕ¼º È¿¼Ò(ò·Û¸ß«ùêà÷ý£áÈ)½Ã½ºÅÛ
  • heme synthetase
    Èû½ÅÅ×Å×À̽º
  • lactose synthetase
    ¶ôÅ佺 ½ÅÅ×Å×À̽º
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • pattern recognition
    ÆÐÅÏÀνÄ, ¸ð¾çÀνÄ
  • recognition
    ÀÎÁö, ÀνÄ
  • site
    À§Ä¡,»çÀÌÆ®
  • web site
    À¥½ÎÀÌÆ®
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
LARS leucyl-tRNA synthetase
TARS threonyl-tRNA synthetase
FS factor of safety; Fanconi syndrome; Felty syndrome; fibromyalgia syndrome; field stimulation; Fisher...
tRNA transfer ribonucleic acid
tRNA GLU transfer ribonucleic acid glutamic acid
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ARS antigen recognition site
SRS substrate recognition site
aa-tRNA Aminoacyl-tRNA
AlaRS Alanyl-tRNA Synthetase
aaRS Aminoacyl-tRNA synthetase
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • antigen recognition site
    Ç׿ø ½Äº°ºÎ
  • recognition site
    ÀÎ½Ä ºÎÀ§
  • synthetase
    ½ÅÅ×Å×À̽º, ½ÅÅןÁ¦, ÇÕ¼º È¿¼Ò
    ATP ȤÀº ±×¿Í À¯»çÇÑ »ïÀλ꿰¿¡¼­
  • dual recognition hypothesis
    2Áß Àνļ³
    ¸é¿ª ¼¼Æ÷ »çÀÌÀÇ »óÈ£ ÀÛ¿ë¿¡ À־ÀÇ T ¼¼Æ÷ÀÇ ÀÎ½Ä ±â±¸¿¡ °üÇÑ °¡¼³ÀÇ Çϳª. T ¼¼Æ÷¿¡´Â ÀÚ±âÀÇ MHC ºÐÀÚ¸¦ ÀνÄÇϱâ À§ÇÑ ¼ö¿ëü¿Í ´Ù¸¥ °ÍÀ» ÀνÄÇϱâ À§ÇÑ ¼ö¿ëü°¡ °¢°¢ µ¶¸³ÇÏ¿© Á¸ÀçÇÑ´Ù°í ÇÏ´Â »ý°¢.
  • antigen binding site
    Ç׿ø °áÇÕ ºÎÀ§
    ¸é¿ª ±Û·ÎºÒ¸°ÀÇ 3Â÷ ±¸Á¶»ó H ¼â¿Í L ¼âÀÇ °¡º¯¿µ¿ª¿¡¼­ ±¸¼ºµÇ¾î ÀÖ´Â Ç׿ø°ú °áÇÕÇÏ´Â ºÎÀ§.
  • antigen combining site
    Ç׿ø °áÇÕºÎ
  • cleavage site
    ºÐ¿­ ºÎÀ§
  • combining site
    °áÇÕºÎ
  • electrophilic site
    Ä£ÀüÀÚ ¹ÝÀÀ¹°
  • molecular site
    ºÐÀÚ À§
  • receptor site
    ¼ö¿ëü ºÎÀ§, ¼ö¿ëºÎ
    ƯÁ¤ÇÑ »ý¹°ÇÐÀû ¹ÝÀÀÀ» ÃÊ·¡ÇÏ´Â ºÐÀÚ °áÇÕÀÌ ÀϾ´Â ƯÁ¤ ºÎÀ§.
  • site
    À§Ä¡, »çÀÌÆ®
  • site of pain modulation
    µ¿Åë Á¶Àý ºÎÀ§
  • specific opiate receptor site
    Ưº°ÇÑ ¾ÆÆí ¼ö¿ëºÎ
  • specific tender point site
    ƯÁ¤ ¾ÐÅëÁ¡
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
p18 component, aminoacyl tRNA synthetase <enzyme> Shares a protein motif with the beta and gamma subunits of eukaryotic elongation factor 1; amino acid sequence given in first source
Registry number: EC 6.1.1.-
Synonym: p18 aminoacyl-trna synthase
(26 Jun 1999)
glutaminyl-tRNA synthetase <enzyme> Pi read RNA, soluble (70-75), but had to be deleted since no longer an active mh
Registry number: EC 6.1.1.18
Synonym: glnrs
(26 Jun 1999)
cysteinyl-tRNA synthetase <enzyme> Spna gene product isolated from bacillus subtilis
Registry number: EC 6.1.1.16
Synonym: spna gene product, cysrs protein
(26 Jun 1999)
threonyl tRNA synthetase kinase <enzyme> From postribosomal supernatants of bom:nmri mouse liver; comigrates with threonyl trna synthetase during several purification steps
Registry number: EC 2.7.1.-
Synonym: thr trna synthetase kinase
(26 Jun 1999)
tRNA pseudouridine synthetase <enzyme> Converts trna-uridine to trna-pseudouridine by intramolecular rearrangement of ribose from n-1 to c-5 position of uracil at positions 38, 39 and 40 of nearly all trnas
Registry number: EC 5.4.99.12
Synonym: pseudoridine synthase I, pus4 gene product, ynl292w gene product
(26 Jun 1999)
tyrosyl tRNA synthetase kinase <enzyme> From postribosomal supernatants of bom:nmri mouse liver; comigrates with tyrosyl trna synthetase during several purification steps
Registry number: EC 2.7.1.-
Synonym: tyr trna synthetase kinase
(26 Jun 1999)
recognition factors Factors which effect "recognition" of target antigens by polymorphonuclear leukocytes; apparently the Fc portion of antibody molecules and the activated third component of complement (C3), for both of which phagocytes have receptor sites.
(05 Mar 2000)
recognition sequence A nucleotide sequence --typically composed of 4, 6, or 8nucleotides -- that is recognised by a restriction endonuclease. Type II enzymes cut (and theircorresponding modification enzymes methylate) within or very near the recognition sequence.
(09 Oct 1997)
recognition time The interval between the application of a stimulus and the recognition of its nature.
(05 Mar 2000)
pattern recognition In information retrieval, machine-sensing or identification of visible patterns (shapes, forms, and configurations). (harrod's librarians' glossary, 7th ed)
(12 Dec 1998)
pattern recognition, visual Visually perceived characters, shapes, displays, or designs.
(12 Dec 1998)
cell recognition <cell biology> Interaction between cells that is possibly dependent upon specific adhesion. Since the mechanism is not entirely clear in most cases, the term should be used with caution.
(26 Mar 1998)
signal recognition particle A complex between a 7S RNA and six proteins. SRP binds to the nascent polypeptide chain of eukaryotic proteins with a signal sequence and halts further translation until the ribosome becomes associated with the rough endoplasmic reticulum. One of the SRP proteins (srp54) binds GTP and in association with 7SRNA and srp19 has GTPase activity.
(18 Nov 1997)
signal recognition particle receptor Receptor for the signal recognition particle (SRP) found in the membrane of the endoplasmic reticulum. Also called docking protein. Heterodimeric, both protomers having GTP binding capacity, though dissimilar binding sites. Not until the complex of SRP, ribosome, message and nascent polypeptide chain binds to the SRP receptor is the block to further chain elongation released and concurrently the SRP is released, leaving the ribosome attached to the endoplasmic reticulum membrane. Cotranslational transport of the polypeptide delivers it into the lumen of the ER.
(18 Nov 1997)
dual recognition hypothesis An outmoded hypothesis that is known to be incorrect now that the structure of the T-cell receptor is known. The proposal was that viral (and some chemical) antigens were recognised in association with histocompatibility antigens by separate receptors on the T-cell. The generation of cytotoxic T-cells was by association with Class I MHC antigens, of T helper cells by association with Class II MHC antigens.
See: altered self hypothesis.
(18 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • recognition
    µ¿ÀÏ(½Ã); ÀÎÁ¤; ½ÂÀÎ
  • recognition
    ÀνÄ;ÀÎÁ¤;ÀÎÁö;½ÂÀÎ;(°ø·Î µîÀ»)¾Ë¾ÆÁÜ;ǥâ;º¸¼ö;º¸´ä;»ç·Ê;¾Ë¾Æº½;¸é½Ä;Àλç;Àý
  • site
    À§Ä¡
  • caravan park (site)
    À̵¿ÁÖÅÃ(Æ®·¹ÀÏ·¯) ÁÖÂ÷Àå
  • ceru(s)site
    ¹é¿¬±¤
  • county seat (site)
    ±ºÃ» ¼ÒÀçÁö;±ºÀÇÇàÁ¤ Áß½ÉÁö
  • launching site
    ¹ß»ç±âÁö
  • receptor site
    ¼¼Æ÷³» ¼ö¿ë ¿µ¿ª
  • restriction site
    Á¦ÇÑ ºÎÀ§(Á¦ÇÑ È¿¼Ò°¡ Àý´ÜÇÏ´Â µÎ ÁÙ »ç½½ DNA»óÀÇ ºÎÀ§)
  • site
    À§Ä¡;Àå¼Ò;¿ëÁö;ºÎÁö !
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á